| Name | Title | Contact Details |
|---|
American Society of Breast Disease is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MemorialCare Health System is a not-for-profit integrated delivery system which includes six top hospitals – Long Beach Memorial Medical Center, Miller Children`s Hospital Long Beach, Community Hospital Long Beach, Orange Coast Memorial Medical Center, Saddleback Memorial Medical Center in Laguna Hills and San Clemente; medical groups – MemorialCare Medical Group, Memorial Prompt Care; an Independent Practice Association (IPA) – Greater Newport Physicians; MemorialCare HealthExpress retail clinics; and numerous outpatient health centers throughout the Southland. An innovator in health care delivery, MemorialCare focuses on evidence-based, best practice medicine. Our physicians and health care professionals study health care`s best practices and work to implement them at all our medical centers. The results are outcomes that frequently exceed state and national averages. MemorialCare has gained widespread recognition for our unique approach to health care. Our system is listed among the top 20 percent of health systems nationwide by Thomson Reuters. In 2011 the organization was identified as one of the top 100 integrated healthcare networks nationwide and top 10 in the west region by IMS.
Convergence Health is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Incline Village, NV. To find more information about Convergence Health, please visit www.convergencehealth.com
Agenus is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants. These programs are supported by three separate technology platforms. Agenus’ internal and partnered checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed programs. The company’s proprietary discovery engine Retrocyte DisplayTM is used to generate fully human and humanized therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus recently acquired a powerful yeast antibody display platform termed SECANT®, developed by Celexion, LLC. SECANT allows rapid generation of soluble, full-length human antibodies. SECANT and Agenus’ mammalian antibody display platform have complementary strengths and further bolster Agenus’ abilities to generate and optimize fully human monoclonal antibodies. Agenus’ heat shock protein-based vaccines have completed Phase 2 studies in newly diagnosed glioblastoma multiforme, and in the treatment of herpes simplex viral infection; the heat shock protein-based vaccine platform can generate personalized as well as off the shelf products. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and with Janssen Sciences Ireland UC and includes several candidates in Phase 2 trials, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials.
DRG International is a Mountainside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.